Functional Compounds of Ginseng and Ginseng-containing Medicine for Treating Cardiovascular Diseases

Overview

Journal Front Pharmacol

Date 2022 Dec 19

PMID 36532771

Authors

Lanchun Liu

Jun Hu

Qiyuan Mao

Chao Liu

Haoqiang He

Xiaoshan Hui

Guang Yang

Peirong Qu

Wenjing Lian

Lian Duan

Yan Dong

Juhua Pan

Yongmei Liu

Qingyong He

Jun Li

Jie Wang

Affiliations

Soon will be listed here.

Abstract

Ginseng (Panax ginseng C.A.Mey.) is the dry root and rhizome of the Araliaceae ginseng plant. It has always been used as a tonic in China for strengthening the body. Cardiovascular disease is still the main cause of death in the world. Some studies have shown that the functional components of ginseng can regulate the pathological process of various cardiovascular diseases through different mechanisms, and its formulation also plays an irreplaceable role in the clinical treatment of cardiovascular diseases. Therefore, this paper elaborates the current pharmacological effects of ginseng functional components in treating cardiovascular diseases, summarizes the adverse reactions of ginseng, and sorts out the Chinese patent medicines containing ginseng formula which can treat cardiovascular diseases.

Citing Articles

Effect of Ginseng Supplementation on Exercise Endurance as a Support for Cardiovascular Disease Management: A Systematic Review and Meta-Analysis.

Szymanska A, Nowak A, Lipert A, Kochan E Antioxidants (Basel). 2025; 14(1).

PMID: 39857366 PMC: 11761553. DOI: 10.3390/antiox14010032.

A review of cardioprotective effect of ginsenosides in chemotherapy-induced cardiotoxicity.

Zare-Zardini H, Hedayati-Goudarzi M, Alizadeh A, Sadeghian-Nodoushan F, Soltaninejad H Biomed Eng Online. 2024; 23(1):128.

PMID: 39709452 PMC: 11662522. DOI: 10.1186/s12938-024-01322-z.

Efficacy and safety of the Chinese herbal medicine Bu-Shen-Huo-Xue granule for the treatment of coronary heart disease: study protocol for a multicenter, randomized, double-blinded, placebo-controlled clinical trial.

Liu L, Wang J, Li J, Li X, Li R, Liu Y Front Cardiovasc Med. 2024; 11:1293818.

PMID: 38895537 PMC: 11184160. DOI: 10.3389/fcvm.2024.1293818.

A Chinese classical prescription Maimendong decoction in treatment of pulmonary fibrosis: an overview.

Lao Q, Wang X, Zhu G, Yuan H, Ma T, Wang N Front Pharmacol. 2024; 15:1329743.

PMID: 38783956 PMC: 11112100. DOI: 10.3389/fphar.2024.1329743.

Shenfu injection: a review of pharmacological effects on cardiovascular diseases.

Xu F, Xie X, Hu H, Tong R, Peng C Front Pharmacol. 2024; 15:1279584.

PMID: 38420190 PMC: 10899515. DOI: 10.3389/fphar.2024.1279584.

References

Zhu H, Luo X, Wang L . [Evaluation on clinical effect of long-term shexiang baoxin pill administration for treatment of coronary heart disease]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010; 30(5):474-7. View

Zhang Y, Zhang X, Li M, Iqbal J, Bourantas C, Li J . The ginsenoside Rg1 prevents transverse aortic constriction-induced left ventricular hypertrophy and cardiac dysfunction by inhibiting fibrosis and enhancing angiogenesis. J Cardiovasc Pharmacol. 2013; 62(1):50-7. DOI: 10.1097/FJC.0b013e31828f8d45. View

Lee H, Lim H, Jun J, Choi J, Lee M . Ginseng for Treating Hypertension: A Systematic Review and Meta-Analysis of Double Blind, Randomized, Placebo-Controlled Trials. Curr Vasc Pharmacol. 2017; 15(6):549-556. DOI: 10.2174/1570161115666170713092701. View

Zheng Q, Bao X, Zhu P, Tong Q, Zheng G, Wang Y . Ginsenoside Rb1 for Myocardial Ischemia/Reperfusion Injury: Preclinical Evidence and Possible Mechanisms. Oxid Med Cell Longev. 2018; 2017:6313625. PMC: 5753014. DOI: 10.1155/2017/6313625. View

Chen F, Huang G . Antioxidant activity of polysaccharides from different sources of ginseng. Int J Biol Macromol. 2018; 125:906-908. DOI: 10.1016/j.ijbiomac.2018.12.134. View

Li J, Shao Z, Xie J, Wang C, Ramachandran S, Yin J . The effects of ginsenoside Rb1 on JNK in oxidative injury in cardiomyocytes. Arch Pharm Res. 2012; 35(7):1259-67. PMC: 3415887. DOI: 10.1007/s12272-012-0717-3. View

Teng C, Kuo S, Ko F, Lee J, Lee L, Chen S . Antiplatelet actions of panaxynol and ginsenosides isolated from ginseng. Biochim Biophys Acta. 1989; 990(3):315-20. DOI: 10.1016/s0304-4165(89)80051-0. View

Duan L, Xiong X, Hu J, Liu Y, Li J, Wang J . Saponins for Treating Coronary Artery Disease: A Functional and Mechanistic Overview. Front Pharmacol. 2017; 8:702. PMC: 5651167. DOI: 10.3389/fphar.2017.00702. View

Boren J, Chapman M, Krauss R, Packard C, Bentzon J, Binder C . Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020; 41(24):2313-2330. PMC: 7308544. DOI: 10.1093/eurheartj/ehz962. View

10.

Gou D, Pei X, Wang J, Wang Y, Hu C, Song C . Antiarrhythmic effects of ginsenoside Rg2 on calcium chloride-induced arrhythmias without oral toxicity. J Ginseng Res. 2020; 44(5):717-724. PMC: 7471212. DOI: 10.1016/j.jgr.2019.06.005. View

11.

Kwon H . Inhibitory Effect of 20(S)-Ginsenoside Rg3 on Human Platelet Aggregation and Intracellular Ca Levels via Cyclic Adenosine Monophosphate Dependent Manner. Prev Nutr Food Sci. 2019; 23(4):317-325. PMC: 6342537. DOI: 10.3746/pnf.2018.23.4.317. View

12.

Zhang N, An X, Lang P, Wang F, Xie Y . Ginsenoside Rd contributes the attenuation of cardiac hypertrophy in vivo and in vitro. Biomed Pharmacother. 2018; 109:1016-1023. DOI: 10.1016/j.biopha.2018.10.081. View

13.

Wang Y, Hu Z, Sun B, Xu J, Jiang J, Luo M . Ginsenoside Rg3 attenuates myocardial ischemia/reperfusion injury via Akt/endothelial nitric oxide synthase signaling and the B‑cell lymphoma/B‑cell lymphoma‑associated X protein pathway. Mol Med Rep. 2015; 11(6):4518-24. DOI: 10.3892/mmr.2015.3336. View

14.

Hien T, Kim N, Kim H, Kang K . Ginsenoside Rg3 inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules in human endothelial cells. Pharmazie. 2010; 65(9):699-701. View

15.

Ryu S, Chien Y . Ginseng-associated cerebral arteritis. Neurology. 1995; 45(4):829-30. DOI: 10.1212/wnl.45.4.829. View

16.

Lu S, Luo Y, Zhou P, Yang K, Sun G, Sun X . Ginsenoside compound K protects human umbilical vein endothelial cells against oxidized low-density lipoprotein-induced injury via inhibition of nuclear factor-κB, p38, and JNK MAPK pathways. J Ginseng Res. 2019; 43(1):95-104. PMC: 6323235. DOI: 10.1016/j.jgr.2017.09.004. View

17.

Chen C, Zhang H . [Protective effect of ginsenoside Re on isoproterenol-induced triggered ventricular arrhythmia in rabbits]. Zhongguo Dang Dai Er Ke Za Zhi. 2009; 11(5):384-8. View

18.

Fulcher J, OConnell R, Voysey M, Emberson J, Blackwell L, Mihaylova B . Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015; 385(9976):1397-405. DOI: 10.1016/S0140-6736(14)61368-4. View

19.

Furukawa T, Bai C, Kaihara A, Ozaki E, Kawano T, Nakaya Y . Ginsenoside Re, a main phytosterol of Panax ginseng, activates cardiac potassium channels via a nongenomic pathway of sex hormones. Mol Pharmacol. 2006; 70(6):1916-24. DOI: 10.1124/mol.106.028134. View

20.

Jin Z, Liu C . Effect of ginsenoside Re on the electrophysiological activity of the heart. Planta Med. 1994; 60(2):192-3. View